Learn more in our bacteriostatic water guide
The clinical investigators specifically noted that "gastrointestinal adverse events were partially mitigated by the use of a lower starting dose." Starting at 1 mg, which is what the Phase 3 TRIUMPH trials use, provides even more tolerability protection
However, researchers with baseline insulin use or sulfonylurea therapy should anticipate potential glucose variability and adjust protocols accordingly
This low dose is not intended to trigger immediate weight loss but to help your body adjust to the medication and minimize the likelihood of common gastrointestinal side effects like nausea and vomiting
Shawn Achtman, DO, ensures the highest quality and safety in all their health products and services
Incidents like this need to be better publicized to raise awareness, said Shabbir Safdar, Executive Director of the Partnership for Safe Medicines